Login
$ENTA
$11.20 +$0.53 (4.97%) After hours

$ENTA 8-K/A SEC Filings

Filed On Filing
07 Mar 2019 8-K/A: Departure/Election of Directors or Officers; Compensation

The purpose of this 2019 Equity Incentive Plan (this “Plan”) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract...

09 May 2017 8-K/A: Results of Operations and Financial Condition

CORRECTING and REPLACING Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2017

24 Nov 2014 8-K/A: Financial Statements and Exhibits

WATERTOWN, Mass., November 24, 2014 — Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today reported finan...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support